KR20220147705A - 종양세포 치사활성 및 항균성 조성물 및 방법 - Google Patents

종양세포 치사활성 및 항균성 조성물 및 방법 Download PDF

Info

Publication number
KR20220147705A
KR20220147705A KR1020227036373A KR20227036373A KR20220147705A KR 20220147705 A KR20220147705 A KR 20220147705A KR 1020227036373 A KR1020227036373 A KR 1020227036373A KR 20227036373 A KR20227036373 A KR 20227036373A KR 20220147705 A KR20220147705 A KR 20220147705A
Authority
KR
South Korea
Prior art keywords
cells
cell
modified
wild
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227036373A
Other languages
English (en)
Korean (ko)
Inventor
한스 쥐. 클링거만
배리 제이. 시몬
Original Assignee
이뮤너티바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤너티바이오, 인크. filed Critical 이뮤너티바이오, 인크.
Priority to KR1020237018562A priority Critical patent/KR20230085215A/ko
Publication of KR20220147705A publication Critical patent/KR20220147705A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227036373A 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법 Ceased KR20220147705A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237018562A KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361899066P 2013-11-01 2013-11-01
US61/899,066 2013-11-01
KR1020217037585A KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
PCT/US2014/062695 WO2015066054A1 (en) 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037585A Division KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018562A Division KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20220147705A true KR20220147705A (ko) 2022-11-03

Family

ID=53005034

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217037585A Active KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020257021166A Pending KR20250099421A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020227036373A Ceased KR20220147705A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020237018562A Ceased KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020167014198A Active KR102329796B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020217037585A Active KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020257021166A Pending KR20250099421A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237018562A Ceased KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020167014198A Active KR102329796B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Country Status (9)

Country Link
US (10) US10258649B2 (enExample)
EP (3) EP3062800B1 (enExample)
JP (2) JP6603216B2 (enExample)
KR (5) KR102476640B1 (enExample)
CN (2) CN120501764A (enExample)
AU (1) AU2014342477B2 (enExample)
CA (1) CA2927977C (enExample)
ES (1) ES2935906T3 (enExample)
WO (1) WO2015066054A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476640B1 (ko) 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
JP2018537536A (ja) * 2015-12-09 2018-12-20 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法
CN109476710B (zh) * 2016-07-19 2021-11-23 国立植物基因组研究所 抗真菌病原体的新蛋白质
EP3519562A4 (en) * 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
CN108324735B (zh) * 2017-01-20 2024-02-09 李莉 用于疾病治疗的胞外体制剂及其应用
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
CN111670246A (zh) * 2018-01-31 2020-09-15 南克维斯特公司 5%人白蛋白在洗涤和收获培养基中的用途
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
EP4013782A4 (en) * 2019-08-12 2023-12-27 Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. IMMUNE COMPOSITION COMPRISING A RESPIRATORY SYNZYTIAL VIRUS (RSV) G POLYPEPTIDE
WO2025221993A1 (en) 2024-04-18 2025-10-23 Immunitybio, Inc. Compositions and methods for producing il-16

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) * 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
JP2007522161A (ja) 2004-02-13 2007-08-09 コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ カスタネア・サチバの葉抽出物を含有する化粧品組成物
JP2008505071A (ja) 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
PL2254586T3 (pl) * 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
ES2577607T3 (es) * 2010-07-28 2016-07-15 Canvax Biotech Sl Nuevos sensores ultrasensibles basados en células y usos de los mismos
KR101298012B1 (ko) 2011-02-08 2013-08-26 (주)차바이오앤디오스텍 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물
US20150212064A1 (en) * 2011-08-12 2015-07-30 The Childrens's Hospital Of Philadelphia Degranulation indicator and methods of use thereof
KR102476640B1 (ko) 2013-11-01 2022-12-09 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
EP3641790A1 (en) 2017-06-20 2020-04-29 Nantkwest, Inc. Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
KR20200035999A (ko) 2017-08-04 2020-04-06 난트케이웨스트, 인크. Nk-92 세포를 이용한 백혈병의 치료 및 억제

Also Published As

Publication number Publication date
EP3701957B1 (en) 2022-12-28
KR20160068976A (ko) 2016-06-15
KR102476640B1 (ko) 2022-12-09
US20220175838A1 (en) 2022-06-09
US20200038445A1 (en) 2020-02-06
EP3062800A4 (en) 2017-04-19
CA2927977A1 (en) 2015-05-07
US20190192570A1 (en) 2019-06-27
AU2014342477B2 (en) 2019-08-01
EP3062800A1 (en) 2016-09-07
KR20250099421A (ko) 2025-07-01
US20190192569A1 (en) 2019-06-27
US10646516B2 (en) 2020-05-12
US12064450B2 (en) 2024-08-20
US20220160768A1 (en) 2022-05-26
AU2014342477A1 (en) 2016-05-26
US20190192568A1 (en) 2019-06-27
US11975027B2 (en) 2024-05-07
KR20210144920A (ko) 2021-11-30
US20160250256A1 (en) 2016-09-01
JP2020073478A (ja) 2020-05-14
CA2927977C (en) 2024-03-05
US20240366674A1 (en) 2024-11-07
US11304977B2 (en) 2022-04-19
ES2935906T3 (es) 2023-03-13
EP4134085A1 (en) 2023-02-15
KR20230085215A (ko) 2023-06-13
EP3701957A1 (en) 2020-09-02
EP3062800B1 (en) 2020-04-08
WO2015066054A1 (en) 2015-05-07
KR102329796B1 (ko) 2021-11-23
US10772912B2 (en) 2020-09-15
US20250170181A1 (en) 2025-05-29
CN105848662A (zh) 2016-08-10
JP6870053B2 (ja) 2021-05-12
JP6603216B2 (ja) 2019-11-06
US11213547B2 (en) 2022-01-04
US20190125801A1 (en) 2019-05-02
JP2016539105A (ja) 2016-12-15
US10517895B2 (en) 2019-12-31
US10258649B2 (en) 2019-04-16
CN120501764A (zh) 2025-08-19

Similar Documents

Publication Publication Date Title
US12064450B2 (en) Tumoricidal and antimicrobial compositions and methods
EP3230318B1 (en) Immune checkpoint inhibitor combinations
ES2877099T3 (es) Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral
KR20220158640A (ko) 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물
HK1228299B (en) Tumoricidal compositions
HK1228299A1 (en) Tumoricidal compositions
EP3197461A1 (en) New immunostimulatory compounds
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221019

Application number text: 1020217037585

Filing date: 20211117

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221117

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221129

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221129

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I